Slide 1: 2016 First nine months
2016 First nine months CONFERENCE CALL – 27 OCTOBER 2016
Slide 2: First nine months 2016 highlights
First nine months 2016 highlights • Revenue € 862,4 million, up 9.9% • EBITDA € 280,0 million or 32.5% of sales, up 16,4% • Operating income (EBIT) € 252,4 million or 29.3% of sales, up 18,5% • Net income € 182,3 million or 21,1% of sales, up 19,5% • Net debt € 100,2 million, an increase of € 11,4 m
Slide 3: Main product sales
Main product sales Corporate products including drugs for rare diseases account for 61.7% of revenue (million Euro) Jan-Sep 2016 Jan-Sep 2015 Change % Zanidip® (lercanidipine) 90.0 89.9 0.1 Zanipress® (lercanidipine+enalapril) 50.8 49.8 2.0 Urorec® (silodosin) 63.3 50.7 24.9 Livazo® (pitavastatin) 2
Slide 4: A diversified product portfolio
A diversified product portfolio Other corporate products 13.3% Drugs for rare diseases 16.3% Livazo® 3.1% Urorec® 7.3% Zanipress® 5.9% OTC 16.4% Zanidip® 10.5% Subsidiaries’ local product portfolios 22.8% Pharmaceutical chemicals 3.5% Ortoton® (methocarbamol) - Germany 3% Other revenue 0.9% Methadon
Slide 5: Composition of revenue by geography
Composition of revenue by geography Sustained growth (million Euro) Jan-Sep 2016 Jan-Sep 2015 Change % Italy 171.2 157.4 8.8 France 84.7 81.6 3.8 U.S.A. 77.4 60.0 28.9 Germany 72.7 68.6 6.0 Turkey 65.8 56.3 17.0 Spain 55.8 53.1 5.2 Russia, other CIS countries and Ukraine 56.1 52.0 7.8 North Africa 3
Slide 6: Geographical breakdown of pharmaceutical revenue
Geographical breakdown of pharmaceutical revenue Other international sales 16.0% (sales to licensees and exports) Italy 20.6% Other CEE 3.0% Other W. Europe 3.3% Portugal 3.5% France 10.2% North Africa 4.1% Russia, other CIS and Ukraine 6.7% U.S.A. 9.3% Spain 6.7% Turkey 7.9% Germany 8.7% Data: Firs
Slide 7: First nine months 2016 results
First nine months 2016 results Further margin growth (million Euro) Jan-Sep 2016 Jan-Sep 2015 Change % Revenue 862.4 784.4 9.9 Gross Profit 595.1 532.8 11.7 as % of revenue 69.0 67.9 SG&A Expenses 273.5 262.5 4.2 as % of revenue 31.7 33.5 R&D Expenses 60.2 55.2 9.0 as % of revenue 7.0 7.0 Other Inco
Slide 8: First nine months 2016 results: Operating segments
First nine months 2016 results Operating segments Revenue EBIT Treatments for rare diseases 16.3% Treatments for rare diseases 25.5% Primary & specialty care Primary & specialty care 83.7% 74.5% EBIT margin on sales: Treatments for rare diseases, 45.7% Primary & Specialty care, 26.1% (or 27,2% exclu
Slide 9: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 30 Sep 2016 31 Dec 2015 Change Cash and short-term financial 191.1 225.5 (34.4) investments Bank overdrafts and short-term loans (13.3) (9.8) (3.5) Loans – due within one year (40.7) (34.5) (6.2) Loans – due after one year (237.3) (269.9) 32
Slide 10: Financial projections: 2016 targets
Financial projections 2016 targets 2015 2016 (million Euro) Actual Targets Revenue 1,047.7 ± 1,140 Operating income 278.5 ± 325 (EBIT) Net Income 198.8 ± 230 10
Slide 11: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan